Q32 Bio Inc.

QTTB

US7469641051

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 08:12:04 16/07/2024 pm IST			5-day change	1st Jan Change
27.39 ^USD	+6.25%		+25.80%	+135.56%

09/07	Q32 Bio Completes Enrollment in Mid-Stage Atopic Dermatitis Trial	MT
09/07	Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis	CI

Homology Medicines, Inc. announced that it has received $23.07 million in funding.

January 06, 2016

On January 6, 2016, Homology Medicines, Inc. closed the transaction. The round included participation 5AM Venture Management LLC including seven investors.

Latest news about Q32 Bio Inc.

Q32 Bio Completes Enrollment in Mid-Stage Atopic Dermatitis Trial	09/07	MT
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis	09/07	CI
Q32 Bio Added to Russell 3000 Index	01/07	MT
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell Small Cap Comp Value Index	01/07	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell Small Cap Completeness Index	01/07	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell 2000 Value Index	01/07	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell 3000 Value Index	01/07	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell 2000 Index	01/07	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell 3000E Index	01/07	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell 2500 Value Index	01/07	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell Microcap Index	01/07	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell 2000 Dynamic Index	01/07	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell Microcap Value Index	01/07	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell 3000E Value Index	01/07	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell 2500 Index	01/07	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell 3000 Index	01/07	CI
Guggenheim Initiates Q32 Bio at Buy With $100 Price Target	17/06	MT
Leerink Partners Starts Q32 Bio With Outperform Rating	21/05	MT
Q32 Bio Inc. Provides Corporate Update	09/05	CI
Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target	11/04	MT
Q32 Bio Inc. Appoints Lee Kalowski as Chief Financial Officer	03/04	CI
Piper Sandler Initiates Q32 Bio With Overweight Rating, $45 Price Target	02/04	MT
Q32 Bio Inc.(NasdaqGM:QTTB) added to NASDAQ Composite Index	26/03	CI
Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from NASDAQ Composite Index	25/03	CI
Q32 Bio Inc. announced that it has received $42 million in funding from a group of investors	25/03	CI

Q32 Bio Inc. is a clinical-stage biotechnology company. The Company is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The Company has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

25.78 USD

Average target price

62.25 USD

Spread / Average Target

+141.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
Q32 BIO INC.	+135.56%	31Cr
VERTEX PHARMACEUTICALS INCORPORATED	+21.28%	13TCr
REGENERON PHARMACEUTICALS, INC.	+24.51%	12TCr
ARGENX SE	+26.49%	2.77TCr
BIONTECH SE	-18.61%	2.03TCr
GENMAB A/S	-15.36%	1.68TCr
BEIGENE, LTD.	-18.06%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+13.39%	1.48TCr
WUXI APPTEC CO., LTD.	-47.70%	1.46TCr
SAREPTA THERAPEUTICS, INC.	+56.88%	1.44TCr

Bio Therapeutic Drugs

Q32 Bio Inc.

Equities

QTTB

US7469641051

Biotechnology & Medical Research

Homology Medicines, Inc. announced that it has received $23.07 million in funding.

Latest news about Q32 Bio Inc.

Chart Q32 Bio Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs